Stock comparison
JOHNSON & JOHNSON is 29.5x more valuable than Royalty Pharma plc by market capitalization ($623.71 B vs $21.16 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
JNJ is larger
JOHNSON & JOHNSON is 29.5x more valuable than Royalty Pharma plc by market capitalization ($623.71 B vs $21.16 B).
Market value leader
JNJ
JOHNSON & JOHNSON is 29.5x more valuable than Royalty Pharma plc by market capitalization ($623.71 B vs $21.16 B).
Revenue leader
JNJ
RPRX: $2.38B vs JNJ: $94.19B.
Profit leader
JNJ
RPRX: $770.95M vs JNJ: $26.80B.
Margin leader
RPRX
RPRX: 32.4% vs JNJ: 28.5% net margin.
| Metric | RPRX | JNJ |
|---|---|---|
| Market cap | $21.16 B | $623.71 B |
| US-listed rank | #608 | #17 |
| Revenue (latest FY) | $2.38B | $94.19B |
| Net income (latest FY) | $770.95M | $26.80B |
| Net margin | 32.4% | 28.5% |
| P/E (trailing FY) | 27.4x | 23.3x |
| SEC filings | 588 | 990 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
JOHNSON & JOHNSON is 29.5x more valuable than Royalty Pharma plc by market capitalization ($623.71 B vs $21.16 B).
In their latest fiscal years, Royalty Pharma plc reported $2.38B in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Royalty Pharma plc and JOHNSON & JOHNSON, or browse the full rankings.